Wienke J, Pachman LM, Morgan GA, et al. - Researchers intended to distinguish inflammation/endothelial dysfunction-related biomarker profiles reflecting disease severity at diagnosis establish whether biomarker profiles can prognosticate response to treatment. This study assessed 39 markers related to endothelial activation, dysfunction, and inflammation in treatment-naive juvenile dermatomyositis (JDM) individual serum from two independent cohorts by multiplex technology. They examined data by unsupervised hierarchical clustering, non-parametric tests with correction for multiple testing, and Kaplan-Meier and cox-proportional-hazards-model for analysis of treatment duration. The lineblot measured myositis-specific antibodies (MSA). The results showed that severe vasculopathy was associated with low ICAM-1 and high endoglin. This study confirms the heterogeneity of new-onset JDM using serum biomarkers. The evidence showed that individuals with high galectin-9, CXCL10, TNFR2, and galectin-1 may respond suboptimally to conventional treatment and may help from more intensive monitoring and/or treatment.